|
USA-WI-SEYMOUR Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- About Us - WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients
- WuXi AppTec - Wikipedia
WuXi AppTec (WuXi is pronounced as Wu-shee) is a global pharmaceutical, biopharmaceutical, and medical device company
- WuXi AppTec
WuXi AppTec is a full-service provider of open-access capabilities and technology that enables customers worldwide to advance discoveries in the health sciences and deliver treatment to those in need Our services include: Chemistry Platform (WuXi Chemistry) Integrated, end-to-end chemistry research, development, and commercial manufacturing
- WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
WuXi AppTec, a global company that provides a broad portfolio of R D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science
- WuXi AppTec Named Top 10 Most Honored Company in Asia Executive . . .
About WuXi AppTec As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients Through its unique business models
- WuXi AppTecs Changzhou and Taixing API Sites Successfully Pass FDA . . .
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China
- Locations - WuXi AppTec DMPK
With five R D centers in the United States (New Jersey) and China (Shanghai, Suzhou, Nanjing, and Nantong), WuXi AppTec DMPK provides services including in vivo and in vitro pharmacokinetics studies, metabolite identification, Non-GLP bioanalysis, radiolabeled compound synthesis, and radiolabeled in vivo PK ADME study
- WuXi AppTec Company Profile - American Pharmaceutical Review
With operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R D and manufacturing services that enable the pharmaceutical and healthcare industries globally to advance discoveries and deliver groundbreaking treatments
- Our Locations - WuXi AppTec
WuXi AppTec (Wuhan) Small molecule drug discovery and research services No 68 Middle Jiulong Road, East Lake High-tech Development Zone, Wuhan, Hubei, 430075, China
- WuXi TIDES
WuXi TIDES, a unique Contract Research and Development Manufacturing Organization (CRDMO) platform, is an integral part of WuXi AppTec WuXi TIDES offers our worldwide partners efficient, flexible, and high-quality solutions for the drug development of oligonucleotides, peptides and related synthetic conjugates (“TIDES” drugs)
|
|